NL-OMON47764已完成2 期
Evaluation of safety and tolerability of pirfenidone in asbestosis, a multicenter study - PIRF-asbestosis
ederlandse vereniging voor artsen voor longziekten en tuberculose NVALT0 个研究点目标入组 10 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Patients (40-85 years) with confirmed asbestosis by Dutch NVALT IPF expertise-panel (History of asbestos exposition with 15-30 years latency ;AND pleural plaques OR asbestos fibers in pulmonary lavage OR asbestos fibers confirmed in lung biopsy), AND criteria 1-6 ;1. written informed consent
- •2. FVC * 50% predicted, DLCO * 25%
- •3. Minimal 6 minute walk test distance 150 meter
- •4. FEV1/FVC > 0.70
- •5. Documented disease progression in 3-6 months (absolute of relative FVC decrease 5% in 3-6 months or absolute or relative DLCOc decrease > 10% in 3-6 months, or decrease * 25 meter on 6 minute walk test in 3-6 months)
排除标准
- •1. current smoker
- •2. > 15% emphysema on HRCT thorax
- •3. >10mg prednisone daily or other immunosuppressant (MTX, azathioprine, cyclophosphamide)
- •4. malignancy
- •5. Hepatic impairment (History of hepatic impairment, elevation of transaminase enzymes, or the confirmation of any of the following liver function test criteria above the specified limits: Total bilirubin above the upper limit of normal (ULN), Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >1.5 × ULN, Alkaline phosphatase > 2.0 × ULN)
- •6. Renal impairment (GFR < 30 ml/min or dialysis)
- •7.Pregnancy
- •8.Concomitant use of a strong and selective inhibitor of CYP1A2 (Fluvoxamin, enoxacin)
研究者
相似试验
进行中（未招募）
1 期
Evaluation of safety and tolerability of pirfenidone in pulmonary scarring due to asbestos, a multicenter studyasbestosisEUCTR2018-001781-41-NLederlandse Vereniging van Artsen voor longziekten en Tuberculose10
尚未招募
Unknown
sefulness of a new medicine -pirfenidone in oral fibrosis due to Arecanut and tobacco useCTRI/2023/04/051723Indian Council of Medical Research
进行中（未招募）
1 期
Standard-armed controlled study to assess the impact of oral Pirfenidone for progressive, non-IPF Lung Fibrosis (RELIEF)1.Fibrotic NSIP., 2.Chronic Hypersensitivity Pneumonitis 3. Lung fibrosis associated with collagen / vascular diseases, 4.Asbestos-induced lung fibrosisMedDRA version: 20.0Level: LLTClassification code 10022612Term: Interstitial lung fibrosisSystem Organ Class: 100000004855MedDRA version: 20.0Level: LLTClassification code 10035754Term: Pneumonitis hypersensitivitySystem Organ Class: 100000004855MedDRA version: 20.0Level: LLTClassification code 10025088Term: Lung fibrosisSystem Organ Class: 100000004855MedDRA version: 20.0Level: LLTClassification code 10022617Term: Interstitial pneumoniaSystem Organ Class: 100000004855EUCTR2014-000861-32-DEJustus Liebig Universität Giessen374
进行中（未招募）
2 期
Exploring Efficacy and Safety of oral Pirfenidone for progressive, non-IPF Lung Fibrosis (RELIEF) -A randomized, double-blind, placebo-controlled, parallel group,multi-center, phase II trialJ84.1J68.4Other interstitial pulmonary diseases with fibrosisChronic respiratory conditions due to chemicals, gases, fumes and vapoursDRKS00009822Justus-Liebig Universität Giessen127
招募中
2 期
Evaluation of Firooz fissure cream containing lanolin in improving the pain and severity of fissure lesionsFissure of nipple.Fissure and fistula of nippleN64.0IRCT20190210042676N27Firooz Health Group Company20